1. Home
  2. OTTR vs ACAD Comparison

OTTR vs ACAD Comparison

Compare OTTR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Otter Tail Corporation

OTTR

Otter Tail Corporation

HOLD

Current Price

$86.23

Market Cap

3.7B

Sector

Utilities

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.88

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTTR
ACAD
Founded
1907
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.9B
IPO Year
2009
2000

Fundamental Metrics

Financial Performance
Metric
OTTR
ACAD
Price
$86.23
$21.88
Analyst Decision
Buy
Analyst Count
0
22
Target Price
N/A
$30.55
AVG Volume (30 Days)
225.5K
1.6M
Earning Date
05-04-2026
05-06-2026
Dividend Yield
2.69%
N/A
EPS Growth
N/A
69.12
EPS
6.55
2.30
Revenue
$1,299,640,000.00
$726,437,000.00
Revenue This Year
$1.99
$18.80
Revenue Next Year
$3.83
$11.70
P/E Ratio
$13.15
$9.45
Revenue Growth
N/A
40.45
52 Week Low
$73.74
$14.08
52 Week High
$92.24
$28.35

Technical Indicators

Market Signals
Indicator
OTTR
ACAD
Relative Strength Index (RSI) 43.25 49.16
Support Level $84.22 $21.51
Resistance Level $89.87 $22.03
Average True Range (ATR) 2.05 0.70
MACD -0.23 0.08
Stochastic Oscillator 18.81 57.43

Price Performance

Historical Comparison
OTTR
ACAD

About OTTR Otter Tail Corporation

Otter Tail Corp is a U.S. energy company that operates in the electric (produces and sells electricity), manufacturing (fabricates metal components), and plastics segments (pipes for water uses). The company conducts its operations and acquires the majority of its revenue in the U.S. in the states of Minnesota, South Dakota, and North Dakota. The majority of the company's revenue is derived from the Electric segment and commercial customers, although it generates revenue from residential and industrial customers, as well.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: